Antiviral Activity of Lactoferrin
  • Pieter J. Swart
  • E. Mirjam Kuipers
  • Catharina Smit
  • Barry W. A. Van Der Strate
  • Martin C. Harmsen
  • Dirk K. F. Meijer
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 443)


A series of native and chemically derivatized lactoferrins (Lfs) purified from milk and colostrum were assayed in vitro for their anti-HIV and anti-HCMV-cytopathic effects in MT4 cells and fibroblasts respectively. All Lfs from bovine and human milk or colostrum were able to completely block HCMV replication as well as inhibited HIV-1 induced cytopathic effects.

Through acylation of the amino function of the lysine residues in Lf, using anhydrides of succinic acid or cis-aconitic acid, negatively charged Lf derivatives were obtained that all showed a strong antiviral activity against the HIV-1 in vitro. Acylated-Lf exhibited a 4-fold stronger antiviral effect on HIV-1 than the parent compound but the activity on HCMV was abolished.

Peptide scanning studies indicated that the native Lf as well as acylated Lf strongly bind to the V3 domain of the HIV envelope protein gp120, with Kd values in the same concentration range as the in vitro IC50. Therefore, shielding of this domain, resulting in inhibition of the virus-cell fusion and entry of the virus in MT4 cells is the likely mechanism underlying the anti-HIV activity.

In contrast, addition of positive charges to Lf through amination of the proteins resulted in an increased anti-HCMV activity and a loss of anti-HIV activity, with antianti-HCMV IC50, values in the low micromolar concentration range. The N-terminal portion of Lf appeared essential to this anti-HCMV effect. The specific distribution of positively and negatively charged domains in the molecule appears to be important in both the anti-HIV and anti-HCMV effects.


Human Serum Albumin Antiviral Activity Succinic Anhydride HCMV Infection HCMV Replication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Plummer G: Cytomegaloviruses of man and animals. Prog Med Virol 1973; 9: 302–340.Google Scholar
  2. 2.
    Weller TH: The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N Engl J Med 1971; 285: 203–214.CrossRefGoogle Scholar
  3. 3.
    Skolnik PR, Kosloff BR, and Hirsch MS: Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis 1988; 157: 508–514.PubMedCrossRefGoogle Scholar
  4. 4.
    Davis MG, Kenney SC, Kamine J, Pagano JS, and Huang ES: Immediate-early gene region of human cytomegalovirus trans-activates the promotor of human immunodeficiency virus. Proc Natl Acad Sci USA 1987; 84: 8642–8646.PubMedCrossRefGoogle Scholar
  5. 5.
    Drew WL, Mintz L, Miner RC, Sands M, and Kettener B: Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis 1981; 143: 188–192.PubMedCrossRefGoogle Scholar
  6. 6.
    Bowden RA: Antivirals for cytomegalovirus. In: Multidisciplinary approach to understanding cytomegalovirus disease. Michelson S, and Plotkin SA (Eds.). Exerpta Medica, Amsterdam, I993,pp. 241–249.Google Scholar
  7. 7.
    Azad RF, Driver VB, Tanaka K, Crooke RM, and Anderson KP: Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 1993; 37: 1945–1954.PubMedCrossRefGoogle Scholar
  8. 8.
    Bryant LA, and Sinclair JH: Inhibition of human cytomegalovirus major immediate early gene expression by antisense RNA expression vectors. J Gen Virol 1993; 74: 1965–1967.PubMedCrossRefGoogle Scholar
  9. 9.
    Snoeck R, Neyts J and De Clercq E: Strategies for the treatment of cytomegalovirus infections. In: Multidisciplinary approach to understanding cytomegalovirus disease. Michelson S, and Plotkin SA (Eds.). Excerpta Medica, Elsevier Science Publishers B.V. Amsterdam, 1993,pp. 269–278.Google Scholar
  10. 10.
    Haas M, Meijer DKF, Moolenaar F, De Jong PE and De Zeeuw D: Renal drug targeting: optimalisation of renal pharmacotherapeutics. In: International Yearbook of Nephrology 1996. Andreucci VE, and Fine LG (Eds.). Oxford University Press, 1996,pp. 3–11.Google Scholar
  11. 11.
    Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DKF, van Asperen J, Borst P, and Schinkel AH: Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdrla P-glycoprotein. Br J Pharmacol 1996; 119: 1038–1044.PubMedCrossRefGoogle Scholar
  12. 12.
    Kuipers ME, Huisman JO, Swart RI, de Bethune M-P, Pauwels R, De Clercq E, Schuitemaker H, and Meijer DKF: Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120. J Acq Immun Defic Synd Hum R 1996; 11: 419–429.CrossRefGoogle Scholar
  13. 13.
    Purtell.IN, Pesce AJ, Clyne DH, Miller WC, and Pollak VE: Isoelectric point of albumin: Effect on renal handling of albumin. Kidney Int 1979; 16: 366–376.CrossRefGoogle Scholar
  14. 14.
    Miyoshi I, Taguchi H, Kubonishi I, Yoshimoto S, Ohtsuki Y, Shiraishi Y, and Akagi T: Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr Cancer Res 1982; 28: 219–228.Google Scholar
  15. 15.
    Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, and De Clercq E: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988; 20: 309–321.PubMedCrossRefGoogle Scholar
  16. 16.
    Pless DP, and Lennarz WJ: Enzymatic conversion of proteins to glycoproteins. Proc Natl Acad Sci USA 1977: 74: 134–138.PubMedCrossRefGoogle Scholar
  17. 17.
    Harmsen MC, Swart PJ, do Bethune M-P, Pauwels R, De Clercq E, The TH, and Meijer DKF: Antiviral effects of plasma and milk proteins: lactoferrin shows potent antiviral activity on both human immunodeficiency virus and human cytomegalovirus. J Infect Dis 1995; 172: 380–388.PubMedCrossRefGoogle Scholar
  18. 18.
    Jansen RW, Schols D, Pauwels R, De Clercq E, and Meijer DKF: Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol Pharmacol 1993; 44: 1003–1007.PubMedGoogle Scholar
  19. 19.
    Swart PJ, and Meijer DKF: Negatively-charged albumins: A novel class of polyanionic proteins with a potent anti-HIV activity. Antiviral News 1994; 2: 69–70.Google Scholar
  20. 20.
    Hasegawa K, Motsuchi W, Tanaka S, and Dosako S: Inhibition with Lactoferrin of In Vitro Infection with Human Herpes Virus. Jpn J Med Sci Biol 1994; 47: 73–85.PubMedGoogle Scholar
  21. 21.
    Metz-Boutigue MH, Jollès J, Mazurier J, Schoentgen F, Legrand D, Spik G, Montreuil J, Jollès P: Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem 1984; 145: 659–676.PubMedCrossRefGoogle Scholar
  22. 22.
    Day CL, Anderson BF, Tweedie JW, and Baker EN: Structure of the Recombinant N-Terminal Lobe of Human Lactoferrin at 2.0 A Resolution. J Mol Biol 1993; 232: 1084–1100.PubMedCrossRefGoogle Scholar
  23. 23.
    Matthews THJ, Lawrence MK, Nair CDG, and Tyrrell DAJ: Antiviral acitivity in milk of possible clinical importance. Lancet 1976; 2: 1387–1389.PubMedCrossRefGoogle Scholar
  24. 24.
    Gold P: Method of treatment of HIV-seropositive individuals with dietary whey proteins. 1994:1–18; PCT/CA93/00107 (Application number);WO 93/20831 (Patent number).Google Scholar
  25. 25.
    Mok J: HIV-1 Infection. Breast Milk and HIV-1 Transmission. Lancet 1993; 341: 930–931.PubMedCrossRefGoogle Scholar
  26. 26.
    Newburg DS, Viscidi RP, Ruff A, and Yolken RH: A human milk factor inhibits binding of human immunodeficiency virus to the CD4 receptor. Pediatr Res 1992; 31: 22–28.PubMedCrossRefGoogle Scholar
  27. 27.
    Lash JA, Coates TD. Lafuze J, Baehner RL, and Boxer LA: Plasma lactoferrin reflects granulocyte activation in vivo. Blood 1983;61:885–888.Google Scholar
  28. 28.
    Boyle MJ, Connors M, Flanigan ME, Geiger SP, Ford H, Baseler M, Adelsberger J, Davey RT, and Lane HC: The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse — A modified human PBL-SCID model for the study of HIV pathogenesis and therapy. J Immunol 1995; 154: 6612–6623.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Pieter J. Swart
    • 1
  • E. Mirjam Kuipers
    • 1
  • Catharina Smit
    • 1
  • Barry W. A. Van Der Strate
    • 1
  • Martin C. Harmsen
    • 2
  • Dirk K. F. Meijer
    • 1
  1. 1.Department of Pharmacology Section Pharmacokinetics and Drug TargetingUniversity of GroningenGroningenThe Netherlands
  2. 2.Department of ImmunologyGroningenThe Netherlands

Personalised recommendations